Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Insights - The company achieved a revenue of 7.49 billion yuan in 2025, a year-on-year increase of 1.2%, while the net profit attributable to shareholders was 178 million yuan, a decrease of 24.6% year-on-year [4][10] - The company's domestic milk powder business faced pressure due to the internal code adjustment, while overseas goat milk powder and cheese businesses showed significant growth [5][8] - The company is expected to recover domestic revenue growth in 2026, driven by the completion of internal code adjustments and a low base in 2025, while overseas markets are projected to maintain high double-digit growth [8] Summary by Sections Revenue and Profit Performance - In 2025, the company reported revenues of 7.49 billion yuan, with a net profit of 178 million yuan, reflecting a decline in profitability due to internal adjustments [4][10] - The second half of 2025 saw revenues of 3.6 billion yuan, a decrease of 3.2% year-on-year, with a net loss of 3 million yuan [4] Product Performance - Revenue breakdown for 2025 includes: cow milk powder (1.767 billion yuan, -16.1%), domestic goat milk powder (2.579 billion yuan, -15.5%), overseas goat milk powder (974 million yuan, +50.7%), nutrition products (320 million yuan, +5.2%), and cheese (1.006 billion yuan, +448.1%) [5] - The overseas goat milk powder business emerged as a key growth driver, with significant revenue increases in the Middle East (45.7% of overseas revenue, +65.5% year-on-year) and North America (39.5% growth) [5][6] Cost and Margin Analysis - The overall gross margin for 2025 was 38.6%, down 3.3 percentage points year-on-year, primarily due to lower margins from the newly consolidated cheese business and rising raw material costs [7] - The company expects an improvement in gross margin in 2026, driven by the completion of internal code systems and an increase in high-margin overseas business [7] Future Outlook - The completion of internal code adjustments is anticipated to stabilize domestic revenue, with expectations for single-digit growth in 2026 [8] - The company is well-positioned for long-term growth, supported by strong brand and channel barriers, particularly in the goat milk powder segment [8]

Core Viewpoint - The company's performance in 2025 is expected to be below expectations due to internal adjustments lagging and a deteriorating external industry environment [4][5]. Group 1: 2025 Performance Forecast - The company is projected to achieve a revenue growth of 1.1% year-on-year in 2025, with a slowdown in growth primarily due to the domestic milk powder business [4]. - The company's net profit attributable to shareholders is expected to remain flat year-on-year in 2025, with a decline in profit in the second half of 2025 mainly due to slower internal code transition and intensified industry competition [4]. Group 2: Factors Affecting Performance - The internal code transition is lagging, with the completion date pushed from Q3 to Q4 2025, disrupting the growth rhythm of core business in the second half of the year [5]. - Increased competition in the industry, with several companies implementing subsidy or price reduction strategies, places the company in a passive position as it is in a price increase phase [5]. - The industry's revenue growth is slowing, which indirectly affects the company's internal code transition progress, making it difficult to achieve the single-digit revenue growth target for 2025 [5]. Group 3: 2026 Outlook - The company is expected to see a moderate improvement in revenue growth in 2026 due to a low base and the completion of the internal code transition, with signs of improvement in market share for both goat and cow milk powder [6]. - The overseas business is anticipated to be a significant growth driver, with stable contributions from markets like the Middle East and Saudi Arabia, and plans to expand into Southeast Asia and North America [6]. - The company has successfully entered overseas pharmaceutical channels and is conducting local pharmaceutical research to enhance competitiveness in international markets, with expectations for rapid growth in overseas revenue in 2026 [6].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [6]. Core Insights - The company is expected to experience a revenue growth of 1.1% year-on-year in 2025, primarily impacted by a slowdown in domestic milk powder business [1]. - The forecasted net profit for 2025 is expected to remain flat compared to the previous year, with a decline in profit anticipated in the second half of 2025 due to slower internal code adjustments and increased industry competition [1][2]. - The company is projected to see a moderate improvement in revenue growth in 2026, supported by the completion of internal code switching and a low base effect from 2025 [3]. Revenue and Profit Forecast - The company's revenue for 2025 is estimated at 7.487 billion yuan, with a slight increase from 2024 [5]. - The net profit for 2025 is projected to be 236 million yuan, remaining stable compared to 2024 [5]. - Earnings per share (EPS) for 2025 is expected to be 0.13 yuan, with a price-to-earnings (P/E) ratio of 13x [4][5]. Market and Competitive Environment - The internal code switching process has been delayed, affecting the company's growth momentum in the second half of 2025 [2]. - Increased competition in the industry has led to other companies offering subsidies or price reductions, putting the company in a disadvantageous position during its price increase phase [2]. - The company’s overseas business is expected to be a significant growth driver, particularly in markets like the Middle East and Southeast Asia, with plans to launch products in India by 2027 [3]. Valuation Metrics - The report adjusts the net profit forecasts for 2025-2027 to 236 million, 262 million, and 280 million yuan respectively, reflecting a cautious outlook due to declining birth rates and intensified competition [4]. - The projected P/E ratios for 2025, 2026, and 2027 are 13x, 12x, and 11x respectively, indicating a relatively stable valuation in the coming years [4].